EpiPens get new lease on life, though not like nationally stockpiled AtroPens got, while B. Cepacia humbles King Bio and valsartan impurity rouses science to action. More drug recalls, more warning letters, more import alerts are announced, while a new counterfeit detector makes its debut.
Drug recalls and shortage alleviation efforts are back in the news.
In mid-August, US FDA eased shortages by giving four more months to expiring Mylan NVEpiPen (epinephrine) auto injectors based on contract manufacturer Pfizer Inc.’s stability studies, But this...